Advanced search
Publication Cover
Pharmaceutical Development and Technology Volume 26, 2021 - Issue 8
Submit an article Journal homepage
261
Views
2
CrossRef citations to date
0
Altmetric
Research Articles

In vitro evaluation of enteral tube administration of lansoprazole orally disintegrating tablets

Alicia Hoovera Division of Pharmaceutical Analysis, Food and Drug Administration, Saint Louis, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0119-3006
ORCID Icon,
Priyanka Chitranshia Division of Pharmaceutical Analysis, Food and Drug Administration, Saint Louis, MO, USA
,
Magdalene Momota Division of Pharmaceutical Analysis, Food and Drug Administration, Saint Louis, MO, USA
,
Katherine Tynerb Office of Pharmaceutical Quality, Food and Drug Administration, Silver Spring, MD, USA
&
Anna Wokovicha Division of Pharmaceutical Analysis, Food and Drug Administration, Saint Louis, MO, USA
Pages 846-851 | Received 31 Jan 2020, Accepted 23 Jun 2021, Published online: 26 Jul 2021

References

  • Baldi F, Malfertheiner P. 2003. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion. 67(1–2):1–5.
  • Blumenstein I, Shastri YM, Stein J. 2014. Gastroenteric tube feeding: techniques, problems and solutions. World J Gastroenterol. 20(26):8505–8524.
  • Brady J, Lee D, Li J. 2017. Polymer Properties and Characterization. Developing Solid Oral Dosage Forms (2nd Edn.), Cambridge, MA: Academic Press.
  • Ekpe A, Jacobsen T. 1999. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography. Drug Dev Ind Pharm. 25(9):1057–1065.
  • Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. 2017. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol. 32(7):1295–1302.
  • FDA 2011. Letter to Healthcare Professionals: Communication on lansoprazole delayed- release orally disintegrating tablets manufactured by Teva Pharmaceuticals. http://www.fda.gov/Drugs/DrugSafety/ucm251485.htm.
  • FDA 2018. Draft guidance on lansoprazole.
  • Fisher C, Blalock B. 2014. Clogged feeding tubes: a clinician's thorn. Pract Gastroenterol Ser. 127:16–22.
  • Food and Drug Administration 2010. The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practices (CGMP)
  • Gao Z, Moore TW, Doub WH, Westenberger BJ, Buhse LF. 2006. Effects of deaeration methods on dissolution testing in aqueous media: a study using a total dissolved gas pressure meter. J Pharm Sci. 95(7):1606–1613.
  • Gremse DA, Donnelly JR, Kukulka MJ, Lloyd E, Lee C. 2004. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther. 19(11):1211–1215.
  • Hoover A, Sun D, Wen H, Jiang W, Cui M, Jiang X, Keire D, Guo C. 2017. In vitro evaluation of nasogastric tube delivery performance of esomeprazole magnesium delayed-release capsules. J Pharm Sci. 106(7):1859–1864.
  • Howden CW. 2005. Review article: immediate-release proton-pump inhibitor therapy-potential advantages. Aliment Pharmacol Ther. 22(s3):25–30.
  • Lucendo AJ, Friginal-Ruiz AB. 2014. Percutaneous endoscopic gastrostomy: an update on its indications, management, complications, and care. Rev Esp Enferm Dig. 106(8):529–539.
  • McClave SA, Neff RL. 2006. Care and long-term maintenance of percutaneous endoscopic gastrostomy tubes. JPEN J Parenter Enteral Nutr. 30(1 Suppl):S27–S38.
  • Nayak AK, Manna K. 2011. Current developments in orally disintegrating tablet technology. J Pharm Educ Res. 2(1):21–34.
  • PREVACID SOLUTAB 2015. (lansoprazole) delayed-release orally disintegrating tablets [package insert], Deerfield, IL: Takeda.
  • Sachs G, Shin JM, Howden CW. 2006. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 23(s2):2–8.
  • Stroud M, Duncan H, Nightingale J. 2003. Guidelines for enteral feeding in adult hospital patients. Gut. 52(90007):1vii–vii12.
  • USP 2017. 41-NF 36: Lansoprazole Delayed-Release Capsules. 2350
  • Wensel TM. 2009. Administration of proton pump inhibitors in patients requiring enteral nutrition. P T. 34(3):143–160.
  • White R, Brandnam V. 2015. Handbook of drug administration via enteral feeding tubes, Third Edition ed.; Pharmaceutical Press: UK.
  • Williams NT. 2008. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 65(24):2347–2357.
  • Wu C, Sun L, Sun J, Yang Y, Ren C, Ai X, Lian H, He Z. 2013. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. Int J Pharm. 453(2):300–306.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.